Fig. 3.

IHMT-MST1-39 reverses diabetic symptoms in the MLD-STZ mouse model of T1D. a–d Fasting blood glucose (caudal vein), food intake and water consumption measurements for once a week. e–f Intra-peritoneal glucose tolerance test (IPGTT) performed during 0 min and 180 min after glucose injection. Respective area-under-the-curve (AUC) shown in f. g, h HbA1c and blood glucose (serum) level was measured by Chemray-240/800. Data were expressed ±SEM. *p < 0.05, IHMT-MST1-39 compared with vehicle group mice; P values determined by Student’s t test